SCHEMBL5651514

SCHEMBL5651514

CN(C(=O)Oc1ccc(CCNS(=O)(=O)N(C)C)cc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 3/20 0.52
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
LIPE Q05469 5/20 0.45
TBXAS1 P24557 2/20 0.44
TBXA2R P21731 1/20 0.44
GAA P10253 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
CA12 O43570 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
POLB P06746 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647611 0.89 RAB9A (0.56) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1
SCHEMBL5685333 0.86 RAB9A (0.50) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1
SCHEMBL5647671 0.83 ALDH1A1 (0.54) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1
SCHEMBL5646623 0.83 ALDH1A1 (0.57) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5649284 0.83 RAB9A (0.57) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1
SCHEMBL5651292 0.82 PRMT1 (0.59) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1
SCHEMBL5652292 0.81 RAB9A (0.46) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1
SCHEMBL5644968 0.80 LMNA (0.49) SMN1; SMN2ALDH1A1LMNATBXAS1TBXA2R
SCHEMBL5644838 0.80 ALDH1A1 (0.67) SMN1; SMN2ALDH1A1MEN1KMT2ATBXAS1
SCHEMBL5652249 0.79 RAB9A (0.62) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL RAB9A 2926/4885SMN1; SMN2 4233/4885NPC1 814/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL RAB9A 3386/4885SMN1; SMN2 4133/4885NPC1 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.